Agarose surface coating influences intracellular accumulation and enhances payload stability of a nano-delivery system

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1520-1530

  De Rosa, Enrica ^a   Chiappini, Ciro ^b   Fan, Dongmei ^a   Liu, Xuewu ^a   Ferrari, Mauro ^a   Tasciotti, Ennio ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

agarose hydrogel; intracellular delivery; nanopores; porous silicon; protein

Indexed keywords

AGAROSE; SILICON;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTERNALIZATION; MATERIAL COATING; NANOFABRICATION; NANOPORE; NANOTECHNOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STABILITY; TISSUE ENGINEERING;

CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; HYDROGEL; MICROSCOPY, CONFOCAL; NANOPARTICLES; POROSITY; SEPHAROSE; SILICON; SURFACE PROPERTIES;

EID: 79959879519     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0453-2     Document Type: Article

References (47)

1. B Leader QJ Baca DE Golan 2008 Protein therapeutics: a summary and pharmacological classification Nat Rev Drug Discov 7 21 39 18097458 10.1038/nrd2399 1:CAS:528:DC%2BD1cXht1ygtQ%3D%3D
2. WJ Murphyand DL Longo 2000 Growth hormone as an immunomodulating therapeutic agent Immunol Today 21 211 3 10.1016/S0167-5699(00)01594-2 (Pubitemid 30259429)
3. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci. 107:3099-3104.
4. JL Rosado NW Solomons R Lisker H Bourges 1984 Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of [beta]-galactosidase to milk at mealtime Gastroenterology 87 1072 82 6434367 1:CAS:528: DyaL2MXitleqsA%3D%3D (Pubitemid 14017075)
5. M Haase 2002 Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates Blood 100 4242 12433699 10.1182/blood-2002-07-2080 1:CAS:528:DC%2BD38XptlGgu78%3D (Pubitemid 35396896)
6. PJ Mease 2000 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 385 90 10972371 10.1016/S0140-6736(00) 02530-7 1:CAS:528:DC%2BD3cXls1Cksr8%3D (Pubitemid 30487495)
7. JD Gorman KE Sack JC Davis 2002 Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor [alpha] N Engl J Med 346 1349 56 11986408 10.1056/NEJMoa012664 1:CAS:528:DC%2BD38Xjt1Shs70%3D (Pubitemid 34754607)
8. W Szmuness 1980 Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States N Engl J Med 303 833 41 6997738 10.1056/NEJM198010093031501 1:STN:280: DyaL3M%2FhtF2itg%3D%3D
9. L Shi 2007 Gardasil: prophylactic human papillomavirus vaccine development [mdash] from bench top to bed-side Clin Pharm Ther 81 259 64 10.1038/sj.clpt.6100055 1:CAS:528:DC%2BD2sXisFyrtbg%3D (Pubitemid 46174823)
10. DB Sodee 2000 Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer Urology 56 988 93 11113745 10.1016/S0090-4295(00)00824-4 1:STN:280:DC%2BD3M7hsFChsw%3D%3D
11. R Taillefer S Edell G Innes J Lister-James 2000 Acute thromboscintigraphy with Tc-99 m-apcitide: results of the phase 3 multicenter clinical trial comparing Tc-99 m-apcitide scintigraphy with contrast venography for imaging acute DVT J Nucl Med 41 1214 23 10914912 1:STN:280:DC%2BD3czpslelsg%3D%3D (Pubitemid 30464005)
12. CA Meier 1994 Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study) J Clin Endocrinol Metab 78 188 96 8288703 10.1210/jc.78.1.188 1:STN:280:DyaK2c7hslKisQ%3D%3D (Pubitemid 24026771)
13. A VeÌgvaÌriand G Marko-Varga 2010 Clinical Protein Science and Bioanalytical Mass Spectrometry with an Emphasis on Lung Cancer Chem Rev 110 3278 98 10.1021/cr100011x
14. D McVey MM Hamilton C Hsu CR King DE Brough LL Wei 2008 Repeat Administration of Proteins to the Eye With a Single Intraocular Injection of an Adenovirus Vector Mol Ther 16 1444 9 18545220 10.1038/mt.2008.124 1:CAS:528:DC%2BD1cXptVWrsr4%3D
15. I Mahmoodand MD Green 2005 Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins Clin Pharmacokinet 44 331 47 10.2165/00003088-200544040-00001 (Pubitemid 40663681)
16. SD Putneyand PA Burke 1998 Improving protein therapeutics with sustained-release formulations Nat Biotech 16 153 7 10.1038/nbt0298-153 (Pubitemid 28078502)
17. K Fu AM Klibanov R Langer 2000 Protein stability in controlled-release systems Nat Biotech 18 24 5 10.1038/71875 1:CAS:528:DC%2BD3cXjs1yruw%3D%3D (Pubitemid 30041164)
18. P Tayaliaand DJ Mooney 2009 Controlled growth factor delivery for tissue engineering Adv Mater 21 3269 85 10.1002/adma.200900241
19. ER Edelman MA Nugent MJ Karnovsky 1993 Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition Proc Natl Acad Sci USA 90 1513 7 8434012 10.1073/pnas.90.4.1513 1:CAS:528:DyaK3sXitVGmtLc%3D (Pubitemid 23058203)
20. DF Lazarous M Shou M Scheinowitz E Hodge V Thirumurti AN Kitsiou JA Stiber AD Lobo S Hunsberger E Guetta SE Epstein EF Unger 1996 Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury Circulation 94 1074 82 8790049 1:CAS:528:DyaK28Xls1Glu7o%3D (Pubitemid 26292864)
21. J Wang KM Chua C-H Wang 2004 Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres J Colloid Interface Sci 271 92 101 14757081 10.1016/j.jcis.2003.08.072 1:CAS:528:DC%2BD2cXmtFeltQ%3D%3D (Pubitemid 38147608)
22. M van de Weert WE Hennink W Jiskoot 2000 Protein Instability in Poly(Lactic-co-Glycolic Acid) microparticles Pharm Res 17 1159 67 11145219 10.1023/A:1026498209874
23. H Sah 1999 Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres PDA J Pharm Sci Technol 53 3 10 10343502 1:CAS:528:DyaK1MXisFaisLY%3D (Pubitemid 29190871)
24. JL Cleland A Mac B Boyd J Yang ET Duenas D Yeung D Brooks C Hsu H Chu V Mukku AJS Jones 1997 The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres Pharm Res 14 420 5 9144725 10.1023/A:1012031012367 1:CAS:528:DyaK2sXjtVWrsLo%3D (Pubitemid 27204998)
25. Canham LT. Bioactive silicon structure fabrication through nanoetching techniques. Advanced Materials. 1995; 7.
26. Voelcker NH, Khung Y-L, Low SP, Clements LR, Williams KA. Porous Silicon Science and Technology Conference, Valencia, 2010.
27. Herino R. In: Canham LT, editor. The properties of porous silicon. London: INSPEC-IEE; 1997.
28. J Salonen AM Kaukonen J Hirvonen VP Lehto 2008 Mesoporous silicon in drug delivery applications J Pharm Sci 97 632 53 17546667 10.1002/jps.20999 1:CAS:528:DC%2BD1cXhvFaksrY%3D (Pubitemid 351293873)
29. C Chiappini E Tasciotti JR Fakhoury D Fine L Pullan Y-C Wang L Fu X Liu M Ferrari 2010 Tailored porous silicon microparticles: fabrication and properties Chemphyschem 11 1029 35 20162656 1:CAS:528:DC%2BC3cXkt1Citbo%3D
30. F Cunin TA Schmedake JR Link YY Li J Koh SN Bhatia MJ Sailor 2002 Biomolecular screening with encoded porous-silicon photonic crystals Nat Mater 1 39 41 12618846 10.1038/nmat702 1:CAS:528:DC%2BD38XntlWlsLs%3D
31. J Linsmeier K Wüst H Schenk U Hilpert W Ossau J Fricke R Arens-Fischer 1997 Chemical surface modification of porous silicon using tetraethoxysilane Thin Solid Films 297 26 30 10.1016/S0040-6090(96)09360-1 1:CAS:528:DyaK2sXktVGiurs%3D (Pubitemid 127401979)
32. C Gurtner AW Wun MJ Sailor 1999 Surface modification of porous silicon by electrochemical reduction of organo halides Angew Chem Int Ed 38 1966 8 10.1002/(SICI)1521-3773(19990712)38:13/14<1966::AID-ANIE1966>3.0.CO;2-5 1:CAS:528:DyaK1MXkslShsbw%3D (Pubitemid 29339677)
33. J Salonen L Laitinen AM Kaukonen J Tuura M Björkqvist T Heikkilä K Vähä-Heikkilä J Hirvonen VP Lehto 2005 Mesoporous silicon microparticles for oral drug delivery: Loading and release of five model drugs J Control Release 108 362 74 16169628 10.1016/j.jconrel.2005.08.017 1:CAS:528:DC%2BD2MXht1aiu7bL (Pubitemid 41608668)
34. CA Prestidge TJ Barnes CH Lau C Barnett A Loni L Canham 2007 Mesoporous silicon: a platform for the delivery of therapeutics Expert Opin Drug Deliv 4 101 10 17335408 10.1517/17425247.4.2.101 1:CAS:528:DC%2BD2sXisVCqurc%3D (Pubitemid 46389909)
35. E Tasciotti XW Liu R Bhavane K Plant AD Leonard BK Price MMC Cheng P Decuzzi JM Tour F Robertson M Ferrari 2008 Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications Nat Nanotechnol 3 151 7 18654487 10.1038/nnano.2008.34 1:CAS:528: DC%2BD1cXivFKgt7w%3D (Pubitemid 351355132)
36. CA Prestidge TJ Barnes A Mierczynska-Vasilev I Kempson F Peddie C Barnett 2008 Peptide and protein loading into porous silicon wafers Phys Status Solidi A 205 311 5 10.1002/pssa.200723113 1:CAS:528:DC%2BD1cXivVahtrk%3D
37. CA Prestidge TJ Barnes A Mierczynska-Vasilev W Skinner F Peddie C Barnett 2007 Loading and release of a model protein from porous silicon powders Phys Status Solidi A 204 3361 6 10.1002/pssa.200723112 1:CAS:528:DC%2BD2sXht1ers7vE (Pubitemid 47608798)
38. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochimica et Biophysica Acta (BBA)-General Subjects. In Press, Corrected Proof:in press (2010).
39. M Kilpeläinen J Riikonen MA Vlasova A Huotari VP Lehto J Salonen KH Herzig K Järvinen 2009 In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles J Control Release 137 166 70 19345247 10.1016/j.jconrel.2009.03.017
40. EJ Anglin MP Schwartz VP Ng LA Perelman MJ Sailor 2004 Engineering the chemistry and nanostructure of porous silicon fabry-pérot films for loading and release of a steroid Langmuir 20 11264 9 15568884 10.1021/la048105t 1:CAS:528:DC%2BD2cXpsV2ntrg%3D
41. T Tanaka LS Mangala PE Vivas-Mejia R Nieves-Alicea AP Mann E Mora HD Han MM Shahzad X Liu R Bhavane J Gu JR Fakhoury C Chiappini C Lu K Matsuo B Godin RL Stone AM Nick G Lopez-Berestein AK Sood M Ferrari 2010 Sustained small interfering RNA delivery by mesoporous silicon particles Cancer Res 70 3687 96 20430760 10.1158/0008-5472.CAN-09-3931 1:CAS:528:DC%2BC3cXltlens7Y%3D
42. T Tanaka B Godin R Bhavane R Nieves-Alicea J Gu X Liu C Chiappini JR Fakhoury S Amra A Ewing Q Li IJ Fidler M Ferrari 2010 In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice Int J Pharm 402 190 7 20883755 10.1016/j.ijpharm.2010.09.015 1:CAS:528:DC%2BC3cXhsVWhu77F
43. P Decuzzi B Godin T Tanaka SY Lee C Chiappini X Liu M Ferrari 2010 Size and shape effects in the biodistribution of intravascularly injected particles J Control Release 141 320 7 19874859 10.1016/j.jconrel.2009.10.014 1:CAS:528:DC%2BC3cXht1KlsL8%3D
44. M Ferrari 2008 Nanogeometry Beyond drug delivery Nat Nano 3 131 2 1:CAS:528:DC%2BD1cXivFKgsbc%3D
45. B Godin J Gu RE Serda R Bhavane E Tasciotti C Chiappini X Liu T Tanaka P Decuzzi M Ferrari 2010 Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation J Biomed Mater Res A 94A 1236 43 1:CAS:528:DC%2BC3cXpvVSrsrY%3D
46. RE Serda A Mack M Pulikkathara AM Zaske C Chiappini JR Fakhoury D Webb B Godin JL Conyers XW Liu JA Bankson M Ferrari 2010 Cellular association and assembly of a multistage delivery system Small 6 1329 40 20517877 10.1002/smll.201000126 1:CAS:528:DC%2BC3cXnvVOlsro%3D
47. S Ferrati A Mack C Chiappini X Liu AJ Bean M Ferrari RE Serda 2010 Intracellular trafficking of silicon particles and logic-embedded vectors Nanoscale 2 1512 20 20820744 10.1039/c0nr00227e 1:CAS:528:DC%2BC3cXhtl2ms73K